Latest News
Sarepta Therapeutics, Inc.
- Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
- Gene Therapy Patent Suit Against Sarepta Comes To Close
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
- Two Stories Ran On Sarepta Therapeutics. Only One Held Up
- Sarepta Therapeutics (SRPT) Holds Near $17.50 as Shares Test Lower Support Zone - IV Rank
- Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
- Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
- Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund
- Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential
- Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27
Headlines from the last 30 days, linking to the original publishers. See all market news →